KUBio Box for Viral Vectors
GE Healthcare Life Sciences launched the new KUBio box for the production of viral vector-based gene therapies.
GE Healthcare Life Sciences launched the new KUBio box for the production of viral vector-based gene therapies. The device is the most recent addition the company’s KUBio modular bioprocessing portfolio.
Designed to fit into new facilities and retrofitted existing spaces, the new device supports up to 200-L scale manufacturing, comes equipped with a biosafety level 2 (BSL-2) modular bioprocessing environment, and features a FlexFactory single-use biomanufacturing platform specifically for the production of viral vectors.
The design also supports future expansion at different production scales and product technologies.
Articles in this issue
Biopharma modeling, now and five years from now
A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU
Modeling Comes of Age in Biopharma
Applying Lessons Learned from the Semiconductor Industry
What’s New in Manufacturing: Downstream Technologies
KUBio Box for Viral Vectors
Zippered Lab Coat
More Consistent Drug Inspection System on Horizon
Signatures–What’s in a Name?
Using TEM-Based Image Analysis to Validate the Presence of HA Spikes on Influenza VLPs
Modernizing Flu Vaccine Manufacturing
New Therapies Present Scaling Challenges
The Principle of Scaling Down
Breaking the Drug Shortage Cycle
Essentials in Bioassay Development
Related Content
